EVGN
Evogene Ltd.
There isn't enough reported data to score EVGN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
EVGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
EVGN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
EVGN PE Valuation
EVGN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
EVGN Forward outlook
There aren't enough analyst estimates for EVGN to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
EVGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.91 | +$1.34 |
| Q1 2026 | -$1.39 | +$1.30 |
| Q4 2025 | -$1.17 | +$1.90 |
| Q3 2025 | -$0.50 | +$3.93 |
| Q2 2025 | -$2.25 | +$1.68 |
| Q1 2025 | -$2.69 | +$1.73 |
| Q4 2024 | -$3.07 | +$2.10 |
EVGN is still losing money, but far less than before: $0.91 per share over the past year, against $5.17 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over EVGN on earnings quality, reporting a profit while its opponent remains loss making.
EVGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $347K | -61% |
| Q1 2026 | $334K | -86% |
| Q4 2025 | $314K | -81% |
| Q3 2025 | $312K | -82% |
| Q2 2025 | $884K | +46% |
| Q1 2025 | $2.4M | -42% |
| Q4 2024 | $1.6M | +179% |
| Q3 2024 | $1.7M | -54% |
EVGN's revenue has slid since its 2024 peak: $347,000 last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -703% | -356 points |
| Q1 2026 | -943% | -774 points |
| Q4 2025 | -1660% | -1376 points |
| Q3 2025 | -873% | -533 points |
| Q2 2025 | -347% | +418 points |
| Q1 2025 | -169% | -71 points |
| Q4 2024 | -283% | +1036 points |
| Q3 2024 | -340% | -229 points |
EVGN's operating margin was −703% last quarter, down 356 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over EVGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over EVGN on profitability, with a higher operating margin.
EVGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | +$224K |
| Q1 2026 | -$3M | +$2.3M |
| Q4 2025 | -$2.7M | +$2.8M |
| Q3 2025 | -$3.8M | +$1.3M |
| Q2 2025 | -$2.3M | +$3.1M |
| Q1 2025 | -$5.3M | -$1.1M |
| Q4 2024 | -$5.5M | +$482K |
| Q3 2024 | -$5.1M | -$527K |
EVGN has burned cash in almost every quarter: −$12M over the past year, against −$18M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over EVGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +2.5M shares |
| 1 year | +69% | +5M shares |
| 3 years | +170% | +7.7M shares |
EVGN has 12M diluted shares, up 69% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EVGN hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over EVGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
EVGN Net Leverage
EVGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
EVGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 10.1 | Oversold |
EVGN's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
EVGN PE vs Healthcare Sector
EVGN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
EVGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.37 | 2.7% below |
| 20 week MA | $0.47 | 23% below |
| 50 week MA | $0.70 | 49% below |
| 100 week MA | $1.00 | 64% below |
| 200 week MA | $3.71 | 90% below |
EVGN is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over EVGN on trend strength, trading above more of its moving averages.
EVGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.6 | $44.1 | +183% |
| 2021 | $44.1 | $17.1 | -61% |
| 2022 | $17.1 | $7.59 | -56% |
| 2023 | $7.59 | $8.40 | +11% |
| 2024 | $8.40 | $1.65 | -80% |
| 2025 | $1.65 | $1.03 | -38% |
| 2026 YTD | $1.03 | $0.36 | -65% |
EVGN's yearly returns have swung widely, from +183% in 2020 to −80% in 2024. It's down 65% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over EVGN on returns for 2026, with the stronger performance.